HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

高风险 B 前体急性淋巴细胞白血病

• 批准号: 7607545
• 负责人: YOUSIF H MATLOUB
• 金额: $ 0.46万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607545
• 关键词: Acute Lymphocytic Leukemia; Chemotherapy-Oncologic Procedure; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Databases; Dexamethasone; Drug usage; Funding; Grant; Institution; Leucovorin Calcium/Methotrexate; Maintenance Therapy; Methotrexate; Methotrexate/Prednisone; National Cancer Institute; Neoadjuvant Therapy; Newly Diagnosed; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; Physician Data Query; Prednisone; Randomized; Research; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; Work; cancer cell; chemotherapy; killings

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. This randomized Phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 （临床试验总结来自国家癌症研究所的PDQ数据库） 化疗中使用的药物，如地塞米松、泼尼松、甲氨蝶呤和亚叶酸钙，以不同的方式阻止癌细胞分裂，使其停止生长或死亡。给予一种以上的药物可能会杀死更多的癌细胞。目前尚不清楚哪种联合化疗方案治疗急性淋巴细胞白血病更有效。 这项随机的III期试验正在研究地塞米松，看看它在诱导治疗中与泼尼松相比的效果如何。该试验还研究了甲氨蝶呤和亚叶酸钙，以观察它们在治疗新诊断的急性淋巴细胞白血病患者的维持治疗中与单独使用甲氨蝶呤相比的效果。